Tumour suppressor protein p53 released by nuclease digestion increases at the onset of rat liver regeneration

Journal of Hepatology

Volumn 31, Issue 2, 1999, Pages 306-314

  Miró, Francesc ^a   Lelong, Jean Claude ^b   Pancetti, Floria ^a,c   Roher, Nerea ^a   Duthu, Arlette ^b   Plana, Maria ^a   Bourdon, Jean Christophe ^b   Bachs, Oriol ^c   May, Evelyne ^b   Itarte, Emilio ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

HepG2; HL 60; Mouse fibroblasts; Protein kinase CK2; Rat hepatic regeneration; Tumour suppressor protein p53

Indexed keywords

NUCLEASE; PROTEIN KINASE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL STRAIN HL 60; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE SEQUENCE; LIVER REGENERATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SEQUENCE ANALYSIS; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 0032776851     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80229-3     Document Type: Article

References (45)

1. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1:1992;45-49.
2. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, et al. Further characterisation of the p53 responsive element - identification of new candidate genes for trans-activation by p53. Oncogene. 14:1997;85-94.
3. Allende JE, Allende CC. Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 9:1995;313-323.
4. Litchfield DW, Lüscher B. Casein kinase II in signal transduction an cell cycle regulation. Mol Cell Biochem. 127/128:1993;187-199.
5. Padmanabha R, Chen-Wu JLP, Hanna D E, Glover CVC. Isolation, sequencing and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae. Mol Cell Biol. 10:1990;4089-4099.
6. Meggio F, Boldyreff B, Marin O, Pinna LA, Issinger O-G. Role of the β subunit of casein kinase-2 on the stability and specificity of the recombinant reconstituted holoenzyme. Eur J Biochem. 204:1992;293-297.
7. Filhol O, Baudier J, Delphin C, Loue-Mackenbach P, Chambaz EM, Cochet C. Casein kinase II and the tumour suppressor protein p53 associate in a molecular complex that is negatively regulated upon p53 phosphorylation. J Biol Chem. 267:1992;20577-20583.
8. Meek DW, Simon S, Kikkawa U, Eckhart W. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J. 10:1990;3253-3260.
9. Hall SR, Campbell LE, Meek DW. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res. 24:1996;1119-1126.
10. Filhol O, Baudier J, Chambaz EM, Cochet C. Casein kinase 2 inhibits the renaturation of complementary DNA strands mediated by p53 protein. Biochem J. 316:1996;331-335.
11. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G. Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem. 271:1996;29380-29385.
12. Pena JM, Itarte E, Domingo A, Cussó R. Cyclic adenosine 3′:5′-monophosphate dependent and independent protein kinase in human leukemic cells. Cancer Res. 43:1983;1172-1175.
13. Daya-Makin M, Sanghera JS, Mogentale TL, Lipp M, Parchomchuk J, Hogg JC, et al. Activation of a tumour-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res. 54:1994;2262-2268.
14. Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science. 267:1995;894-897.
15. Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase II alpha. EMBO J. 15:1996;5160-5166.
16. Lorenz P, Pepperkok R, Ansorge W, Pyerin W. Cell biological studies with monoclonal and polyclonal antibodies against human casein kinase II subunit β demonstrate participation of the kinase in mitogenic signalling. J Biol Chem. 268:1993;2733-2739.
17. 1/S phases of the cell cycle. J Biol Chem. 269:1994;6986-6991.
18. 2/M in Saccharomyces cerevisiae. J Biol Chem. 270:1995;25905-25915.
19. Perez M, Grande J, Itarte E. Casein kinase 2 activity increases in the prereplicative phase of liver regeneration. FEBS Lett. 238:1988;273-276.
20. Pancetti F, Bosser R, Itarte E Bachs O. Changes in the activity of nuclear protein kinase CK2 during rat liver regeneration. Biochem Biophys Res Comm. 218:1996;35-39.
21. Thompson NL, Mead JE, Braun L, Goyette M, Shank PR, Fausto N. Sequential protooncogene expression during rat liver regeneration. Cancer Res. 46:1986;3111-3117.
22. Kren BT, Trembley JH, Steer CJ. Alterations in mRNA stability during rat liver regeneration. Am J Physiol. 33:1996;G763-G777.
23. Wilcock D, Lane DP. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature. 349:1991;429-431.
24. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 9:1995;41-47.
25. May E, Jenkins JR, May P. Endogenous HeLa p53 protein are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene. Oncogene. 6:1991;1363-1365.
26. Molina E, Plana M, Itarte E. Heterogeneity of rat liver cytosol casein kinase 2. Biochem J. 277:1991;811-818.
27. Gurney EG, Harrison RO, Fenno J. Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct subclasses of large T antigen and for similarities among nonviral T antigens. J Virol. 34:1980;752-763.
28. David-Pfeuty T, Chakrani F, Ory C, Nouvian-Dooghe Y. Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumours cells and untransformed cells. Cell Growth Differ. 7:1996;1211-1215.
29. Bosser R, Roig J, Itarte E, Bachs O. Casein kinase 2 and protein substrates are released from rat liver cells nuclei by DNase or RNase digestion. Biochem Biophys Res Commun. 202:1994;984-991.
30. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA. 87:1990;1973-1977.
31. Wirkner U, Voss H, Ansorge W, Pyerin W. Genomic organization and promoter identification of the human protein kinase CK2 catalytic subunit α (CSNK2A1). Genomics. 48:1998;71-78.
32. Xu X, Rich Jr ES, Seldin DC. Murine protein kinase CK2α′: cDNA and genomic cloning and chromosomal mapping. Genomics. 48:1998;79-86.
33. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumour antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA. 82:1985;790-794.
34. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 8:1993;2457-2467.
35. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
36. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:1993;4164-4168.
37. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046-1049.
38. Raycroft L, Wu H, Lozano G. Transcriptional activation by wildtype but not transforming mutants of the p53 anti-oncogene. Science. 249:1990;1049-1051.
39. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome- mediated degradation of p53. Cancer Res. 56:1996;2649-2654.
40. Molinari M, Okorokov AL, Milner J. Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding. Oncogene. 13:1996;2077-2086.
41. Milner J, Milner S. SV40-53K antigen: a possible role for 53K in normal cells. Virology. 112:1981;785-788.
42. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
43. El-Deiry WS, Tokino T, Velculescu VE, Levy DL, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumour suppression. Cell. 75:1993;817-825.
44. Shivakumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol. 15:1995;6785-6793.
45. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-225.